advertisement
11.14 Investigational drugs; pharmacological experiments (24)
Showing records 1 to 24
Display all abstracts in classification 11.14 Investigational drugs; pharmacological experiments
Search within classification 11.14 Investigational drugs; pharmacological experiments45634 Real-time measurements of nicotinamide adenine dinucleotide in live human trabecular meshwork cells: Effects of acute oxidative stress
Masihzadeh O; Ammar DA; Lei TC; Gibson EA; Kahook MY
Experimental Eye Research 2011;
46301 Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death
Gregory MS; Hackett CG; Abernathy EF; Lee KS; Saff RR; Hohlbaum AM; Moody KL; Hobson MW; Jones A; Kolovou P
PLoS ONE 2011; 6: e17659
46168 Current and emerging medical therapies in the treatment of glaucoma
Bagnis A; Papadia M; Scotto R; Traverso CE
Expert Opinion on Emerging Drugs 2011; 16: 293-307
46112 Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
Duncan RS; Xin H; Goad DL; Chapman KD; Koulen P
Clinical Ophthalmology 2011; 5: 543-548
45491 Rasagiline-induced Delay of Retinal Ganglion Cell Death in Experimental Glaucoma in Rats
Levkovitch-Verbin H; Vander S; Melamed S
Journal of Glaucoma 2011; 20: 273-277
45733 A selective inhibitor of Drp1, Mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina
Park SW; Kim K-Y; Lindsey JD; Dai Y; Heo H; Nguyen DH; Ellisman MH; Weinreb RN; Ju W-K
Investigative Ophthalmology and Visual Science 2011; 52: 2837-2843
46102 Closed gateways- Can neuroprotectants shield the retina in glaucoma?
Velpandian T
Drugs in R&D 2010; 10: 93-96
46103 Visual field protective effect of erigeron breviscapus (vant.) hand. mazz. extract on glaucoma with controlled intraocular pressure: A randomized, double-blind, clinical trial
Zhong Y; Xiang M; Ye W; Cheng Y; Jiang Y
Drugs in R&D 2010; 10: 75-82
45658 Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits
Alarma-Estrany P; Guzman-Aranguez A; Huete F; Peral A; Plourde Jr R; Pelaez T; Yerxa B; Pintor J
Journal of Pharmacology and Experimental Therapeutics 2011; 337: 703-709
46317 Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors
Chen YT; Vojkovsky T; Fang X; Pocas JR; Grant W; Handy AMW; Schroter T; LoGrasso P; Bannister TD; Feng Y
MedChemComm 2011; 2: 73-75
45942 Biological activity of quinoxaline derivatives
Deepika Y; Nath PS; Sachin K; Shewta S
International Journal of Current Pharmaceutical Review and Research 2011; 2: 33-46
45630 A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs
Impagnatiello F; Borghi V; Gale DC; Batugo M; Guzzetta M; Brambilla S; Carreiro ST; Chong WKM; Prasanna G; Chiroli V
Experimental Eye Research 2011;
45627 Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2(alpha) agonist, in preclinical models
Krauss AHP; Impagnatiello F; Toris CB; Gale DC; Prasanna G; Borghi V; Chiroli V; Chong WKM; Carreiro ST; Ongini E
Experimental Eye Research 2011;
45922 Synthesis and crystallographic analysis of new sulfonamides incorporating NO-donating moieties with potent antiglaucoma action
Mincione F; Benedini F; Biondi S; Cecchi A; Temperini C; Formicola G; Pacileo I; Scozzafava A; Masini E; Supuran CT
Bioorganic and Medicinal Chemistry Letters 2011; 21: 3216-3221
45628 Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma
Prasanna G; Carreiro S; Anderson S; Gukasyan H; Sartnurak S; Younis H; Gale D; Xiang C; Wells P; Dinh D
Experimental Eye Research 2011;
46130 (alpha)2C-adrenoceptor modulators: A patent review
Quaglia W; Del Bello F; Giannella M; Piergentili A; Pigini M
Expert Opinion on Therapeutic Patents 2011; 21: 455-481
45687 Combined treatment in patients with unstabilized glaucoma
Shtilerman AL; Mikhal'skii EA; Lysiak IV
Vestnik Oftalmologii 2010; 126: 28-31
46063 Protective effect of a JNK inhibitor against retinal ganglion cell loss induced by acute moderate ocular hypertension
Sun H; Wang Y; Pang I-H; Shen J; Tang X; Li Y; Liu C; Li B
Molecular Vision 2011; 17: 864-875
45642 Functional and morphological effects of (beta)-estradiol in eyes with N-methyl-d-Aspartate-induced retinal neurotoxicity in rats
Yamashita H; Yamada-Nakayama C; Sugihara K; Tsuji S; Sakurai T; Ban Y; Tsutsumi S; Sato Y
Experimental Eye Research 2011;
45734 The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
Andres-Guerrero V; Molina-Martinez IT; Pera A; de las Heras B; Pintor J; Herrero-Vanrell R
Investigative Ophthalmology and Visual Science 2011; 52: 1507-1515
46186 Enhanced Solubility, Stability, and Transcorneal Permeability of Delta-8-Tetrahydrocannabinol in the Presence of Cyclodextrins
Hippalgaonkar K; Gul W; Elsohly MA; Repka MA; Majumdar S
AAPS PharmSciTech 2011;
45947 Inhibition of TGF beta 2 shRNA on human Tenon's capsular fibroblasts
Luo W; Sun L; Li J-M
Chinese Ophthalmic Research 2010; 28: 1150-1153
45945 Inhibition effect of P27 tumor suppressor gene transfection on human Tenon's fibroblast cells
Sun L; Luo W; Li J-M
Chinese Ophthalmic Research 2010; 28: 1119-1123
45944 Effects of huoxuehuayu prescription on retina with acute intraocular hypertension
Zhang C; Wang D-B; Fang J; Shang W-W
Chinese Ophthalmic Research 2010; 28: 1129-1133
